Drug & intervention

niraparib

RxCUI 1918231

Clinical trials44
Recruiting4
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…

Clinical trials

40 shown
Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLCNCT05718323 · 2023-12-20
RECRUITING
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast CancerNCT05601440 · 2023-06-13
RECRUITING
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate CancerNCT04947254 · 2021-08-05
RECRUITING
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib StudyNCT04641247 · 2021-04-16
RECRUITING
SMMART Adaptive Clinical Treatment (ACT) TrialNCT05238831 · 2023-01-30
WITHDRAWN
Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination DeficiencyNCT05461690 · 2022-09-01
UNKNOWN
The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung CancerNCT05162196 · 2022-06-01
UNKNOWN
PARP-inhibitor on Advanced Metastatic Breast Cancer in Germline PALB2 Mutations CarriersNCT05232006 · 2022-05-01
NOT_YET_RECRUITING
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated TumorsNCT05169437 · 2022-03-15
TERMINATED
A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast CancerNCT05261269 · 2022-02-02
COMPLETED
Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal CancerNCT04673448 · 2021-10-18
ACTIVE_NOT_RECRUITING
A Study of ART4215 for the Treatment of Advanced or Metastatic Solid TumorsNCT04991480 · 2021-09-13
COMPLETED
Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast CancerNCT04837209 · 2021-07-21
ACTIVE_NOT_RECRUITING
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular DiseaseNCT04915755 · 2021-06-28
ACTIVE_NOT_RECRUITING
Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid TumorsNCT04764084 · 2021-04-01
UNKNOWN
LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast CancerNCT04762901 · 2021-04-01
WITHDRAWN
Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine CarcinomasNCT04701307 · 2021-02-01
ACTIVE_NOT_RECRUITING
Niraparib + Dostarlimab In BRCA Mutated Breast CancerNCT04584255 · 2021-01-21
ACTIVE_NOT_RECRUITING
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate CancerNCT04592237 · 2020-12-29
ACTIVE_NOT_RECRUITING
Study of M4344 in Combination With NiraparibNCT04655183 · 2020-12-01
WITHDRAWN
A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate CancerNCT04577833 · 2020-11-13
ACTIVE_NOT_RECRUITING
A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate CancerNCT04194554 · 2020-11-06
ACTIVE_NOT_RECRUITING
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung CancerNCT04475939 · 2020-10-26
COMPLETED
Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN)NCT04240106 · 2020-06-15
COMPLETED
ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian CancerNCT04267939 · 2020-02-26
TERMINATED
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response DefectsNCT04030559 · 2020-02-25
TERMINATED
Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of RecurringNCT04037254 · 2019-10-08
COMPLETED
Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast CancerNCT03368729 · 2019-09-06
ACTIVE_NOT_RECRUITING
A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer PatientsNCT03945721 · 2019-07-11
ACTIVE_NOT_RECRUITING
Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung CancerNCT03891615 · 2019-06-06
TERMINATED
Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line ChemotherapyNCT03830918 · 2019-03-06
ACTIVE_NOT_RECRUITING
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate CancerNCT03748641 · 2019-01-25
ACTIVE_NOT_RECRUITING
A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer PatientsNCT02826512 · 2018-05-15
TERMINATED
Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Breast CancerNCT03329937 · 2018-04-12
COMPLETED
Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042NCT03307785 · 2017-10-12
COMPLETED
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer ParticipantsNCT03308942 · 2017-09-29
COMPLETED
Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)NCT03076203 · 2017-09-22
COMPLETED
PEN-866 in Patients With Advanced Solid MalignanciesNCT03221400 · 2017-08-29
UNKNOWN
Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and BreastNCT03154281 · 2017-07-26
COMPLETED
A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)NCT02924766 · 2016-10-03
COMPLETED

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.